(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Brazil's ex-president Bolsonaro operated on for hernia - 2Vote in favor of your Number one natural product
- 3Tasting America: An Excursion Through Darling Cheap Food Brands
- 4Putting pig organs in people is OK in the US, but growing human organs in pigs is not – why is that?
- 5Famous Network programs in Europe and America
- The Main 15 Applications for Efficiency and Association
- The most effective method to Boost Eco-friendliness in Your Volvo XC40
- MacArthur Foundation awards $100M to outbreak surveillance network, a boost amid global health cuts
- The Conclusive Manual for Spending plan Travel: Opening Undertakings on a Tight budget
- How did Ariana Grande get her Glinda voice? I’m the man behind the magic.
- The most effective method to Consummate the Specialty of Handshaking in Business and Group environments
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Thorough Aide
- Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
- Germany's Deutsche Welle broadcaster declared 'undesirable' in Russia
